@article{9f0aaf59d31042b99c5b1b9afe00b001,
title = "Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States",
abstract = "Our whole genome sequence (WGS) pipeline was assessed for accurate prediction of antimicrobial phenotypes. For 2316 invasive pneumococcal isolates recovered during 2015 we compared WGS pipeline data to broth dilution testing (BDT) for 18 antimicrobials. For 11 antimicrobials categorical discrepancies were assigned when WGS-predicted MICs and BDT MICs predicted different categorizations for susceptibility, intermediate resistance or resistance, ranging from 0.9% (tetracycline) to 2.9% (amoxicillin). For β-lactam antibiotics, the occurrence of at least four-fold differences in MIC ranged from 0.2% (meropenem) to 1.0% (penicillin), although phenotypic retesting resolved 25%–78% of these discrepancies. Non-susceptibility to penicillin, predicted by penicillin-binding protein types, was 2.7% (non-meningitis criteria) and 23.8% (meningitis criteria). Other common resistance determinants included mef (475 isolates), ermB (191 isolates), ermB + mef (48 isolates), tetM (261 isolates) and cat (51 isolates). Additional accessory resistance genes (tetS, tet32, aphA-3, sat4) were rarely detected (one to three isolates). Rare core genome mutations conferring erythromycin-resistance included a two-codon rplD insertion (rplD69-KG-70) and the 23S rRNA A2061G substitution (six isolates). Intermediate cotrimoxazole-resistance was associated with one or two codon insertions within folP (238 isolates) or the folA I100L substitution (38 isolates), whereas full cotrimoxazole-resistance was attributed to alterations in both genes (172 isolates). The two levofloxacin-resistant isolates contained parC and/or gyrA mutations. Of 11 remaining isolates with moderately elevated MICs to both ciprofloxacin and levofloxacin, seven contained parC or gyrA mutations. The two rifampin-resistant isolates contained rpoB mutations. WGS-based antimicrobial phenotype prediction was an informative alternative to BDT for invasive pneumococci.",
keywords = "Accessory genome, Core genome, Minimum inhibitory concentrations, Pneumococcal, Whole genome",
author = "{Active Bacterial Core surveillance team} and Metcalf, {B. J.} and S. Chochua and Gertz, {R. E.} and Z. Li and H. Walker and T. Tran and Hawkins, {P. A.} and A. Glennen and R. Lynfield and Y. Li and L. McGee and B. Beall and A. Reingold and S. Brooks and H. Randel and L. Miller and B. White and D. Aragon and M. Barnes and J. Sadlowski and S. Petit and M. Cartter and C. Marquez and M. Wilson and M. Farley and S. Thomas and A. Tunali and W. Baughman and L. Harrison and J. Benton and T. Carter and R. Hollick and K. Holmes and A. Riner and C. Holtzman and R. Danila and K. MacInnes and K. Scherzinger and K. Angeles and J. Bareta and L. Butler and S. Khanlian and R. Mansmann and M. Nichols and N. Bennett and S. Zansky and S. Currenti and S. McGuire and A. Thomas and M. Schmidt",
note = "Funding Information: Major funding for this work was provided through support from the Advanced Molecular Detection (AMD) initiative at CDC. We are grateful to the Minnesota Department of Public Health laboratory for susceptibility testing of all isolates recovered in Minnesota. We thank the following individuals for their contributions to the establishment and maintenance of the ABCs system. California Emerging Infections Program: A. Reingold, S. Brooks and H. Randel. Colorado Emerging Infections Program: L. Miller, B. White, D. Aragon, M. Barnes and J. Sadlowski. Connecticut Emerging Infections Program: S. Petit, M. Cartter, C. Marquez and M. Wilson. Georgia Emerging Infections Program: M. Farley, S. Thomas, A. Tunali and W. Baughman. Maryland Emerging Infections Program: L. Harrison, J. Benton, T. Carter, R. Hollick, K. Holmes and A. Riner. Minnesota Emerging Infections Program: C. Holtzman, R. Danila and K. MacInnes. New Mexico Emerging Infections Program: K. Scherzinger, K. Angeles, J. Bareta, L. Butler, S. Khanlian, R. Mansmann and M. Nichols. New York Emerging Infections Program: N. Bennett, S. Zansky, S. Currenti and S. McGuire. Oregon Emerging Infections Program: A. Thomas, M. Schmidt, J. Thompson and T. Poissant. Tennessee Emerging Infections Program: W. Schaffner, B. Barnes, K. Leib, K. Dyer and L. McKnight. CDC: R. Gierke, O. Almendares, J. Hudson, L. McGlone and G. Langley. Publisher Copyright: {\textcopyright} 2016",
year = "2016",
month = dec,
day = "1",
doi = "10.1016/j.cmi.2016.08.001",
language = "English (US)",
volume = "22",
pages = "1002.e1--1002.e8",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "12",
}